198
Participants
Start Date
August 14, 2019
Primary Completion Date
December 10, 2020
Study Completion Date
June 17, 2021
BT-11 (440 mg)
Oral, once daily tablet
BT-11 (880 mg)
Oral, once daily tablet
Placebo
Oral, once daily tablet
Polyclinic Duvnjak, Zagreb
Smart Medical Research, Richmond Hill
Invesclinic.U.S,LLC.FL, Fort Lauderdale
Medycal Research Inc., Brooksville
I.H.S Health LLC, Kissimmee
"Municipal Non-profit Enterprise City Outpatient Clinic No 9 of Kharkiv City Council, Surgery department, Kharkiv", Kharkiv
RIVERM E D Sp. zo.o., Poznan
Multidisciplinary Medical Center of Odesa National Medical University, First Surgery Department ,Odesa National Medical University , Chair of General and Military Surgeon, Odesa
"Polyclinic and Daily hospital Dr Al Tawil", Sarajevo
Cantonal Hospital Zenica, Gastroenterology, Zenica
Texas Gastroenterology Associates, Spring
Invesclinic.U.S,LLC., McAllen
Centrum Badan Klinicznych PI-House Sp. z o.o., Gdansk
Axis Clinical Trials, Los Angeles
Ventura Clinical Trials, Ventura
Clinical Research of California, Walnut Creek
Lead Sponsor
NImmune Biopharma
INDUSTRY